EGF receptor family: Twisting targets for improved cancer therapies

Antony W. Burgess; Yoav I. Henis; Nancy E. Hynes; Thomas Jovin; Alexander Levitzki; Ronit Pinkas-Kramarski; Yosef Yarden

doi:10.3109/08977194.2014.896355

EGF receptor family: Twisting targets for improved cancer therapies

Antony W. Burgess^*, Yoav I. Henis, Nancy E. Hynes, Thomas Jovin, Alexander Levitzki, Ronit Pinkas-Kramarski, Yosef Yarden

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The epidermal growth factor receptor (EGFR) undergoes a conformational change in response to ligand binding. The ligand-induced changes in cell surface aggregation and mobility have a profound effect on the function of all the family members. Ligand also activates the EGFR intracellular kinase, stimulating proliferation and cell survival. The EGFR family are often activated, overexpressed or mutated in cancer cells and therapeutic drugs (including antibodies) can slow the progress of some cancers. This article provides a brief, annotated summary of the presentations and discussion which occurred at the Epidermal Growth Factor Receptor-Future Directions Conference held in Jerusalem in November 2013.

Original language	English
Pages (from-to)	74-81
Number of pages	8
Journal	Growth Factors
Volume	32
Issue number	2
DOIs	https://doi.org/10.3109/08977194.2014.896355
State	Published - Apr 2014

Keywords

Cell surface
ErbB2
ErbB3
FLIM
FRET
Receptor dynamics
Therapeutic antibodies

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/08977194.2014.896355

Cite this

@article{9f9446651bd142669b2fe15e08896dc2,

title = "EGF receptor family: Twisting targets for improved cancer therapies",

abstract = "The epidermal growth factor receptor (EGFR) undergoes a conformational change in response to ligand binding. The ligand-induced changes in cell surface aggregation and mobility have a profound effect on the function of all the family members. Ligand also activates the EGFR intracellular kinase, stimulating proliferation and cell survival. The EGFR family are often activated, overexpressed or mutated in cancer cells and therapeutic drugs (including antibodies) can slow the progress of some cancers. This article provides a brief, annotated summary of the presentations and discussion which occurred at the Epidermal Growth Factor Receptor-Future Directions Conference held in Jerusalem in November 2013.",

keywords = "Cell surface, ErbB2, ErbB3, FLIM, FRET, Receptor dynamics, Therapeutic antibodies",

author = "Burgess, {Antony W.} and Henis, {Yoav I.} and Hynes, {Nancy E.} and Thomas Jovin and Alexander Levitzki and Ronit Pinkas-Kramarski and Yosef Yarden",

note = "Funding Information: The Institute for Advanced Studies and the Israel Science Foundation, Eli Lilly and Genentech Inc. provided the generous financial support which made the conference possible.",

year = "2014",

month = apr,

doi = "10.3109/08977194.2014.896355",

language = "אנגלית",

volume = "32",

pages = "74--81",

journal = "Growth Factors",

issn = "0897-7194",

publisher = "Informa Healthcare",

number = "2",

}

TY - JOUR

T1 - EGF receptor family

T2 - Twisting targets for improved cancer therapies

AU - Burgess, Antony W.

AU - Henis, Yoav I.

AU - Hynes, Nancy E.

AU - Jovin, Thomas

AU - Levitzki, Alexander

AU - Pinkas-Kramarski, Ronit

AU - Yarden, Yosef

N1 - Funding Information: The Institute for Advanced Studies and the Israel Science Foundation, Eli Lilly and Genentech Inc. provided the generous financial support which made the conference possible.

PY - 2014/4

Y1 - 2014/4

N2 - The epidermal growth factor receptor (EGFR) undergoes a conformational change in response to ligand binding. The ligand-induced changes in cell surface aggregation and mobility have a profound effect on the function of all the family members. Ligand also activates the EGFR intracellular kinase, stimulating proliferation and cell survival. The EGFR family are often activated, overexpressed or mutated in cancer cells and therapeutic drugs (including antibodies) can slow the progress of some cancers. This article provides a brief, annotated summary of the presentations and discussion which occurred at the Epidermal Growth Factor Receptor-Future Directions Conference held in Jerusalem in November 2013.

AB - The epidermal growth factor receptor (EGFR) undergoes a conformational change in response to ligand binding. The ligand-induced changes in cell surface aggregation and mobility have a profound effect on the function of all the family members. Ligand also activates the EGFR intracellular kinase, stimulating proliferation and cell survival. The EGFR family are often activated, overexpressed or mutated in cancer cells and therapeutic drugs (including antibodies) can slow the progress of some cancers. This article provides a brief, annotated summary of the presentations and discussion which occurred at the Epidermal Growth Factor Receptor-Future Directions Conference held in Jerusalem in November 2013.

KW - Cell surface

KW - ErbB2

KW - ErbB3

KW - FLIM

KW - FRET

KW - Receptor dynamics

KW - Therapeutic antibodies

UR - http://www.scopus.com/inward/record.url?scp=84896904110&partnerID=8YFLogxK

U2 - 10.3109/08977194.2014.896355

DO - 10.3109/08977194.2014.896355

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:84896904110

SN - 0897-7194

VL - 32

SP - 74

EP - 81

JO - Growth Factors

JF - Growth Factors

IS - 2

ER -

EGF receptor family: Twisting targets for improved cancer therapies

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this